A study of the effectiveness and side effects of first-line amivantamab plus lazertinib combination therapy for advanced or recurrent EGFR-mutated non-small cell lung cancer

Authors
Category Primary study
Registry of TrialsUMIN Clinical Trials Registry
Year 2026
This article has no abstract
Epistemonikos ID: 3e199fc4857660d8e3a02fda85869aa04006143e
First added on: Oct 10, 2026